| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Myriad Genetics (NASDAQ:MYGN) is set to give its latest quarterly earnings report on Monday, 2025-11-03. Here's what investors need to know before the announcement.
Analysts estimate that Myriad Genetics will report an earnings per share (EPS) of $-0.05.
The announcement from Myriad Genetics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
Last quarter the company beat EPS by $0.10, which was followed by a 46.51% increase in the share price the next day.
Here's a look at Myriad Genetics's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.05 | 0.03 | 0.02 |
| EPS Actual | 0.05 | -0.03 | 0.03 | 0.06 |
| Price Change % | 47.00 | -41.00 | -15.00 | -1.00 |
Shares of Myriad Genetics were trading at $7.95 as of October 30. Over the last 52-week period, shares are down 54.77%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
To track all earnings releases for Myriad Genetics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MYGN
